Eton Pharmaceuticals is a specialty pharmaceutical company focused on rare diseases and other underserved patient groups, often via reformulated or hospital-oriented products. It develops, acquires and commercializes therapies intended to fill gaps where few branded options exist. Customers are primarily U.S. clinicians, hospitals and specialty pharmacies serving pediatric and rare-condition populations.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 18.9 | — | -2.6 | — |
| Q3 2025 | 22.5 | — | -1.9 | — |
| Q4 2025 | 21.3 | — | 1.5 | — |
| Q1 2026 | 24.3 | — | 1.6 | — |
| Q2 2026 | 37.6 | 98.6% | 11.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Pagaya Technologies Ltd. (PGY), Ascentage Pharma Group Internat (AAPG), Hillman Solutions Corp. (HLMN), Ultragenyx Pharmaceutical Inc. (RARE), Certara, Inc. (CERT), Keel Infrastructure Corp. (KEEL)